Review



computer‐generated randomisation schedule  (Glaxo Smith)

 
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Glaxo Smith computer‐generated randomisation schedule
    <xref ref-type= Lacerda 2019 " width="250" height="auto" />
    Computer‐Generated Randomisation Schedule, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/computer+generated+randomisation+schedule/computer+generated+randomization+schedule/pmc08094590-85-16-20
    Average 90 stars, based on 1 article reviews
    computer‐generated randomisation schedule - by Bioz Stars, 2026-11
    90/100 stars

    Images

    1) Product Images from "Tafenoquine for preventing relapse in people with Plasmodium vivax malaria"

    Article Title: Tafenoquine for preventing relapse in people with Plasmodium vivax malaria

    Journal: The Cochrane Database of Systematic Reviews

    doi: 10.1002/14651858.CD010458.pub3

    <xref ref-type= Lacerda 2019 " title="Lacerda 2019" property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Lacerda 2019

    Techniques Used: Activity Assay, Infection, Sequencing, Selection

    <xref ref-type= Llanos‐Cuentas 2014 " title="Llanos‐Cuentas 2014" property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Llanos‐Cuentas 2014

    Techniques Used: Activity Assay, Infection, Sequencing, Selection, Generated

    Related Articles

    Generated:

    Article Title: Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial
    Article Snippet: Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA (F M Marty MD); Servei d’Urgències, Hospital Universitari Son Espases, Palma de Mallorca, Illes Balears, Spain (J Vidal-Puigserver PhD); Department of Emergency Medicine, William Beaumont Hospital, Royal Oak, MI, USA (C Clark MD); M V Hospital & Research Centre, Lucknow, India (S K Gupta MD); Hospital General Universitario de Alicante, Alicante, Spain (E Merino PhD); Service de Réanimation Polyvalente, Hôpital Bretonneau, Tours, France (D Garot MD); Royal Adelaide Hospital, Adelaide, Australia (M J Chapman PhD); Infectious Diseases Department, CUB-Erasme, Université Libre de Bruxelles, Brussels, Belgium (F Jacobs PhD); Infectología, Hospital Civil de Guadalajara Fray Antonio Alcalde; Instituto de Patología Infecciosa y Experimental, CUCS, UDG Guadalajara, Jalisco, Mexico (E Rodriguez-Noriega PhD); Department of Infectious Diseases, Faculty of Medicine, Masaryk University; University Hospital Brno, Czech Republic (P Husa PhD); PAREXEL International, Research Triangle Park, NC, USA (D Shortino MS); GlaxoSmithKline, Stockley Park, Middlesex, UK (H A Watson MSc); GlaxoSmithKline, Stevenage, Herts, UK (P J Yates PhD); and GlaxoSmithKline, Boston, MA, USA (A F Peppercorn MD) Intravenous zanamivir or oral oseltamivir for hospitalised patients with infl uenza: an international, randomised, double-blind, double-dummy, phase 3 trial

    Article Title: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
    Article Snippet: Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Hans Jaeger, Catherine Orrell, Firaya Nagimova, Fritz Bredeek, Miguel García Deltoro, Susan Swindells, Jaime Federico Andrade-Villanueva, Alexander Wong, Marie-Aude Khuong-Josses, Rodica Van Solingen-Ristea, Veerle van Eygen, Herta Crauwels, Susan Ford, Christine Talarico, Paul Benn, Yuanyuan Wang, Krischan J Hudson, Vasiliki Chounta, Amy Cutrell, Parul Patel, Mark Shaefer, David A Margolis, Kimberly Y Smith, Simon Vanveggel, William Spreen

    Software:

    Article Title: Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial
    Article Snippet: Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA (F M Marty MD); Servei d’Urgències, Hospital Universitari Son Espases, Palma de Mallorca, Illes Balears, Spain (J Vidal-Puigserver PhD); Department of Emergency Medicine, William Beaumont Hospital, Royal Oak, MI, USA (C Clark MD); M V Hospital & Research Centre, Lucknow, India (S K Gupta MD); Hospital General Universitario de Alicante, Alicante, Spain (E Merino PhD); Service de Réanimation Polyvalente, Hôpital Bretonneau, Tours, France (D Garot MD); Royal Adelaide Hospital, Adelaide, Australia (M J Chapman PhD); Infectious Diseases Department, CUB-Erasme, Université Libre de Bruxelles, Brussels, Belgium (F Jacobs PhD); Infectología, Hospital Civil de Guadalajara Fray Antonio Alcalde; Instituto de Patología Infecciosa y Experimental, CUCS, UDG Guadalajara, Jalisco, Mexico (E Rodriguez-Noriega PhD); Department of Infectious Diseases, Faculty of Medicine, Masaryk University; University Hospital Brno, Czech Republic (P Husa PhD); PAREXEL International, Research Triangle Park, NC, USA (D Shortino MS); GlaxoSmithKline, Stockley Park, Middlesex, UK (H A Watson MSc); GlaxoSmithKline, Stevenage, Herts, UK (P J Yates PhD); and GlaxoSmithKline, Boston, MA, USA (A F Peppercorn MD) Intravenous zanamivir or oral oseltamivir for hospitalised patients with infl uenza: an international, randomised, double-blind, double-dummy, phase 3 trial

    Article Title: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
    Article Snippet: Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Hans Jaeger, Catherine Orrell, Firaya Nagimova, Fritz Bredeek, Miguel García Deltoro, Susan Swindells, Jaime Federico Andrade-Villanueva, Alexander Wong, Marie-Aude Khuong-Josses, Rodica Van Solingen-Ristea, Veerle van Eygen, Herta Crauwels, Susan Ford, Christine Talarico, Paul Benn, Yuanyuan Wang, Krischan J Hudson, Vasiliki Chounta, Amy Cutrell, Parul Patel, Mark Shaefer, David A Margolis, Kimberly Y Smith, Simon Vanveggel, William Spreen

    other:

    Article Title: Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study
    Article Snippet: Methods In this double-blind, randomised, dose-ranging phase 2b study, men and women (aged ≥16 years) with microscopically confi rmed P vivax monoinfection (parasite density >100 to <100 000 per μL blood) were enrolled from community health centres and hospitals across seven sites in Brazil, Peru, India, and Thailand.. Patients with glucose6-phosphate dehydrogenase enzyme activity of less than 70% were excluded.. Eligible patients received chloroquine (days 1−3) and were randomly assigned (1:1:1:1:1:1) by a computer-generated randomisation schedule to receive singledose tafenoquine 50 mg, 100 mg, 300 mg, or 600 mg, primaquine 15 mg for 14 days, or chloroquine alone.

    Article Title: Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial
    Article Snippet: Patients were randomised centrally across all sites in accordance with a computer-generated randomisation schedule validated by GlaxoSmithKline.



    Similar Products

    90
    Veristat Inc computer-generated participant identification number and randomisation schedule with block randomisation
    Computer Generated Participant Identification Number And Randomisation Schedule With Block Randomisation, supplied by Veristat Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/computer+generated+randomisation+schedule/computer+generated+participant+identification+number+and+randomisation+schedule+with+block+randomisation/10__1016_slash_s0140___6736_ascii40_23_ascii41_02190___6-67-22-8
    Average 90 stars, based on 1 article reviews
    computer-generated participant identification number and randomisation schedule with block randomisation - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Janssen computer-generated randomisation schedule
    Computer Generated Randomisation Schedule, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/computer+generated+randomisation+schedule/randomisation+sequence/10__1016_slash_s0140___6736_ascii40_22_ascii41_00688___2-39-6-19
    Average 90 stars, based on 1 article reviews
    computer-generated randomisation schedule - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Glaxo Smith computer‐generated randomisation schedule
    <xref ref-type= Lacerda 2019 " width="250" height="auto" />
    Computer‐Generated Randomisation Schedule, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/computer+generated+randomisation+schedule/computer+generated+randomization+schedule/pmc08094590-85-16-20
    Average 90 stars, based on 1 article reviews
    computer‐generated randomisation schedule - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    SAS institute computer-generated randomisation schedules
    <xref ref-type= Lacerda 2019 " width="250" height="auto" />
    Computer Generated Randomisation Schedules, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/computer+generated+randomisation+schedule/computer+generated+randomization+list/10__1016_slash_s1473___3099_ascii40_20_ascii41_30023___2-72-7-15
    Average 90 stars, based on 1 article reviews
    computer-generated randomisation schedules - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Pfizer Inc computer-generated randomised schedule
    <xref ref-type= Lacerda 2019 " width="250" height="auto" />
    Computer Generated Randomised Schedule, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/computer+generated+randomisation+schedule/computer+generated+randomisation+list/pmc06614921-2004-24-4
    Average 90 stars, based on 1 article reviews
    computer-generated randomised schedule - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    GraphPad Software Inc computer generated randomisation schedule
    <xref ref-type= Lacerda 2019 " width="250" height="auto" />
    Computer Generated Randomisation Schedule, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/computer+generated+randomisation+schedule/computer+generated+randomization+list/pmc06375188-78-17-12
    Average 90 stars, based on 1 article reviews
    computer generated randomisation schedule - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    STATA Corporation computer-generated randomised treatment allocation schedule
    The count of strata incorporated within the <t> block-randomised </t> 1:1 hypothermia / normothermia <t> treatment allocation schedule </t>
    Computer Generated Randomised Treatment Allocation Schedule, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/computer+generated+randomisation+schedule/computer+generated+randomised+treatment+allocation+schedule/pmc05923032-66-2-7
    Average 90 stars, based on 1 article reviews
    computer-generated randomised treatment allocation schedule - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Glaxo Smith computer-generated randomisation schedule
    The count of strata incorporated within the <t> block-randomised </t> 1:1 hypothermia / normothermia <t> treatment allocation schedule </t>
    Computer Generated Randomisation Schedule, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/computer+generated+randomisation+schedule/computer+generated+randomization+schedule/10__1016_slash_s1474___4422_ascii40_16_ascii41_30399___4-28-11-16
    Average 90 stars, based on 1 article reviews
    computer-generated randomisation schedule - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Almirall Hermal computer generated randomisation schedule
    ACCLAIM/COPD I
    Computer Generated Randomisation Schedule, supplied by Almirall Hermal, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/computer+generated+randomisation+schedule/computer+generated+randomisation+schedule/pmc08922974-902-16-11
    Average 90 stars, based on 1 article reviews
    computer generated randomisation schedule - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    <xref ref-type= Lacerda 2019 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Tafenoquine for preventing relapse in people with Plasmodium vivax malaria

    doi: 10.1002/14651858.CD010458.pub3

    Figure Lengend Snippet: Lacerda 2019

    Article Snippet: Random sequence generation (selection bias) , Low risk , Quote: "With the use of a computer‐generated randomisation schedule provided by GlaxoSmithKline, on day 1 eligible participants were randomly assigned, in a 2:1:1 ratio…".

    Techniques: Activity Assay, Infection, Sequencing, Selection

    <xref ref-type= Llanos‐Cuentas 2014 " width="100%" height="100%">

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Tafenoquine for preventing relapse in people with Plasmodium vivax malaria

    doi: 10.1002/14651858.CD010458.pub3

    Figure Lengend Snippet: Llanos‐Cuentas 2014

    Article Snippet: Random sequence generation (selection bias) , Low risk , Quote: "With the use of a computer‐generated randomisation schedule provided by GlaxoSmithKline, on day 1 eligible participants were randomly assigned, in a 2:1:1 ratio…".

    Techniques: Activity Assay, Infection, Sequencing, Selection, Generated

    The count of strata incorporated within the  block-randomised  1:1 hypothermia / normothermia  treatment allocation schedule

    Journal: Trials

    Article Title: Statistical analysis plan for the POLAR-RCT: The Prophylactic hypOthermia trial to Lessen trAumatic bRain injury-Randomised Controlled Trial

    doi: 10.1186/s13063-018-2610-y

    Figure Lengend Snippet: The count of strata incorporated within the block-randomised 1:1 hypothermia / normothermia treatment allocation schedule

    Article Snippet: The computer-generated randomised treatment allocation schedule (using Stata version 11 ralloc module http://fmwww.bc.edu/repec/bocode/r/ralloc.ado ) [ ] was stratified by hospital group or pre-hospital paramedic ambulance service with a permuted block scheme.

    Techniques: Blocking Assay, Western Blot

    ACCLAIM/COPD I

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Aclidinium bromide for stable chronic obstructive pulmonary disease

    doi: 10.1002/14651858.CD010509.pub2

    Figure Lengend Snippet: ACCLAIM/COPD I

    Article Snippet: Although not explicitly described in the trial reports, from correspondence all Almirall ‐sponsored trials applied a computer generated randomisation schedule which was prepared prior to initiating the trial.

    Techniques: Control, Biomarker Discovery, Infection, Comparison, Medications, Sequencing, Selection, Generated, Blocking Assay

    ACCLAIM/COPD II

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Aclidinium bromide for stable chronic obstructive pulmonary disease

    doi: 10.1002/14651858.CD010509.pub2

    Figure Lengend Snippet: ACCLAIM/COPD II

    Article Snippet: Although not explicitly described in the trial reports, from correspondence all Almirall ‐sponsored trials applied a computer generated randomisation schedule which was prepared prior to initiating the trial.

    Techniques: Control, Biomarker Discovery, Infection, Comparison, Medications, Sequencing, Selection, Generated, Blocking Assay

    ACCORD COPD I

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Aclidinium bromide for stable chronic obstructive pulmonary disease

    doi: 10.1002/14651858.CD010509.pub2

    Figure Lengend Snippet: ACCORD COPD I

    Article Snippet: Although not explicitly described in the trial reports, from correspondence all Almirall ‐sponsored trials applied a computer generated randomisation schedule which was prepared prior to initiating the trial.

    Techniques: Control, Infection, Comparison, Medications, Sequencing, Selection, Generated, Blocking Assay

    ACCORD COPD II

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Aclidinium bromide for stable chronic obstructive pulmonary disease

    doi: 10.1002/14651858.CD010509.pub2

    Figure Lengend Snippet: ACCORD COPD II

    Article Snippet: Although not explicitly described in the trial reports, from correspondence all Almirall ‐sponsored trials applied a computer generated randomisation schedule which was prepared prior to initiating the trial.

    Techniques: Control, Infection, Comparison, Medications, Concentration Assay, Sequencing, Selection, Generated, Blocking Assay

    ACLIFORM

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Aclidinium bromide for stable chronic obstructive pulmonary disease

    doi: 10.1002/14651858.CD010509.pub2

    Figure Lengend Snippet: ACLIFORM

    Article Snippet: Although not explicitly described in the trial reports, from correspondence all Almirall ‐sponsored trials applied a computer generated randomisation schedule which was prepared prior to initiating the trial.

    Techniques: Control, Infection, Transplantation Assay, Functional Assay, Comparison, Sequencing, Selection, Generated, Blocking Assay

    ATTAIN

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Aclidinium bromide for stable chronic obstructive pulmonary disease

    doi: 10.1002/14651858.CD010509.pub2

    Figure Lengend Snippet: ATTAIN

    Article Snippet: Although not explicitly described in the trial reports, from correspondence all Almirall ‐sponsored trials applied a computer generated randomisation schedule which was prepared prior to initiating the trial.

    Techniques: Control, Biomarker Discovery, Infection, Comparison, Medications, Sequencing, Selection, Generated, Blocking Assay

    AUGMENT COPD

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Aclidinium bromide for stable chronic obstructive pulmonary disease

    doi: 10.1002/14651858.CD010509.pub2

    Figure Lengend Snippet: AUGMENT COPD

    Article Snippet: Although not explicitly described in the trial reports, from correspondence all Almirall ‐sponsored trials applied a computer generated randomisation schedule which was prepared prior to initiating the trial.

    Techniques: Control, Infection, Comparison, Sequencing, Selection, Generated, Blocking Assay

    Beier 2013

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Aclidinium bromide for stable chronic obstructive pulmonary disease

    doi: 10.1002/14651858.CD010509.pub2

    Figure Lengend Snippet: Beier 2013

    Article Snippet: Although not explicitly described in the trial reports, from correspondence all Almirall ‐sponsored trials applied a computer generated randomisation schedule which was prepared prior to initiating the trial.

    Techniques: Control, Biomarker Discovery, Infection, Comparison, Medications, Sequencing, Selection, Generated, Blocking Assay

    Chanez 2010

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Aclidinium bromide for stable chronic obstructive pulmonary disease

    doi: 10.1002/14651858.CD010509.pub2

    Figure Lengend Snippet: Chanez 2010

    Article Snippet: Although not explicitly described in the trial reports, from correspondence all Almirall ‐sponsored trials applied a computer generated randomisation schedule which was prepared prior to initiating the trial.

    Techniques: Control, Biomarker Discovery, Infection, Comparison, Medications, Activity Assay, Sequencing, Selection, Generated, Blocking Assay

    NCT01572792

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Aclidinium bromide for stable chronic obstructive pulmonary disease

    doi: 10.1002/14651858.CD010509.pub2

    Figure Lengend Snippet: NCT01572792

    Article Snippet: Although not explicitly described in the trial reports, from correspondence all Almirall ‐sponsored trials applied a computer generated randomisation schedule which was prepared prior to initiating the trial.

    Techniques: Control, Comparison, Sequencing, Selection, Generated, Blocking Assay

    Sliwinski 2010

    Journal: The Cochrane Database of Systematic Reviews

    Article Title: Aclidinium bromide for stable chronic obstructive pulmonary disease

    doi: 10.1002/14651858.CD010509.pub2

    Figure Lengend Snippet: Sliwinski 2010

    Article Snippet: Although not explicitly described in the trial reports, from correspondence all Almirall ‐sponsored trials applied a computer generated randomisation schedule which was prepared prior to initiating the trial.

    Techniques: Control, Comparison, Sequencing, Selection